Back to top

smart-health: Archive

Urmimala Biswas

Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?

TEM surged 34.5% in Q2 on AI-driven deals and product momentum, but valuation and profit concerns linger ahead of earnings.

AZNPositive Net Change TXGNegative Net Change SOPHPositive Net Change TEMNegative Net Change

Urmimala Biswas

Tempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare?

Tempus AI surges 91.8% YTD with soaring genomics revenues and a $200M AstraZeneca deal, outpacing NVIDIA in AI healthcare gains.

AZNPositive Net Change NVOPositive Net Change NVDANegative Net Change TEMNegative Net Change